MS drug in breastmilk: new study checks baby safety

NCT ID NCT04998851

Completed Knowledge-focused Sponsor: Hoffmann-La Roche Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at how much of the multiple sclerosis drug ocrelizumab gets into breastmilk and whether it affects babies' immune cells. Twenty-six breastfeeding mothers with MS or clinically isolated syndrome took part. Researchers measured drug levels in breastmilk and checked B cell counts in their infants after the mothers received their first postpartum dose.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ocrelizumab
What this could lead to: If successful, this study could help doctors understand whether it is safe for mothers with MS to breastfeed while taking ocrelizumab.
What could go wrong: This is a small, completed study with only 26 participants, so results may not apply to all mothers. It only measured short-term effects on infants.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CLINICALLY ISOLATED SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Breast Feeding multiple sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CLINICALLY ISOLATED SYNDROME MULTIPLE SCLEROSIS

Contacts and locations

Locations

Brigham and Womens Hospital

Boston, Massachusetts, 02115, United States
Hosp. Clinico San Carlos

Madrid, 28040, Spain
Hospital of the University of Pennsylvania

Philadelphia, Pennsylvania, 19104, United States
Memorial Healthcare Institute for Neurosciences and Multiple Sclerosis

Owosso, Michigan, 48867, United States
Northwestern Memorial Hospital

Chicago, Illinois, 60611-2987, United States
Queen Mary University of London

London, EC1M 6BQ, United Kingdom
University Of Colorado

Aurora, Colorado, 80045, United States
University of California San Francisco

San Francisco, California, 94158, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.